fda and compounded semaglutide Ends GLP-1s: What to Know FDA warns about compounded versions

Their active ingredient, semaglutide, belongs to a class of GLP-1 receptor agonists that work to reduce weight by mimicking a naturally occurring hormone that signals your body to feel full and slows digestion by increasing the time it takes for food to leave the body

FINAL DIAGNOSIS Exudative pleural and pericardial effusions associated with semaglutide

Lilly is developing it for obesity, type 2 diabetes and related conditions

Your PCP is a natural starting point if theyre actively managing obesity treatment

If youve been reading this newsletter, you know Ive written about the fact that OA patients on GLP-1 drugs report pain improvement long before any meaningful weight loss occurs

Kennedy currently serves as the U.S